DAIR联合骨内万古霉素治疗膝关节假体周围感染
本研究回顾性分析35例膝关节假体周围感染患者,在DAIR时联合骨内注射万古霉素500 mg,至少随访12个月。急性感染非复发率为92.3%(24/26),慢性不可切除感染仅为44.4%(4/9);MSIS宿主分级是失败显著指标(p < 0.001)。结论认为该方案安全且结果优于标准DAIR,但慢性感染需谨慎。
要点
- DAIR联合骨内万古霉素对急性膝关节PJI非复发率达92.3%。
- 慢性不可切除感染非复发率仅44.4%,应谨慎使用。
- MSIS宿主分级是失败显著指标(p < 0.001)。
核心结论
- DAIR时加用骨内万古霉素安全,结果优于当前不使用骨内抗生素的标准DAIR文献。
- 该技术用于慢性感染应谨慎,需更长随访才能广泛采用。
研究设计与样本
- 回顾性病例系列,35例膝关节假体周围感染TKA患者,中位年龄67岁(IQR 61-75),至少随访12个月。
- 26例为原发假体急性围手术期或急性血源性感染,9例为慢性感染且组件被认为不可切除。
- 主要结局定义为无因感染再手术且无PJI临床体征或症状。
主要发现
- 急性感染平均随访16.5个月(12.1-24.2),慢性不可切除感染平均随访15.8个月(12-24.8)。
- 急性感染总体非复发率为92.3%(24/26),慢性不可切除感染仅为44.4%(4/9)。
- 多数患者继续口服抑制性抗生素。
- MSIS宿主分级是失败的显著指标(p < 0.001)。
关键数值与推荐
- DAIR联合骨内万古霉素500 mg单次给药。
- 急性感染非复发率92.3%(24/26),慢性不可切除感染44.4%(4/9)。
- MSIS宿主分级与失败显著相关(p < 0.001)。
临床怎么用
- 对急性膝关节PJI行DAIR时可考虑加用单次骨内万古霉素500 mg。
- 慢性感染且组件不可切除者应谨慎使用该技术。
- 需评估MSIS宿主分级以预测失败风险。
局限性
- 回顾性病例系列,样本量小(35例)。
- 慢性感染亚组仅9例,随访时间较短。
- 需更长随访才能广泛采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Debridement, antibiotics, and implant retention (DAIR) remains one option for the treatment of acute periprosthetic joint infection (PJI) despite imperfect success rates. Intraosseous (IO) administration of vancomycin results in significantly increased local bone and tissue concentrations compared to systemic antibiotics alone. The purpose of this study was to evaluate if the addition of a single dose of IO regional antibiotics to our protocol at the time of DAIR would improve outcomes. METHODS: A retrospective case series of 35 PJI TKA patients, with a median age of 67 years (interquartile range (IQR) 61 to 75), who underwent DAIR combined with IO vancomycin (500 mg), was performed with minimum 12 months' follow-up. A total of 26 patients with primary implants were treated for acute perioperative or acute haematogenous infections. Additionally, nine patients were treated for chronic infections with components that were considered unresectable. Primary outcome was defined by no reoperations for infection, nor clinical signs or symptoms of PJI. RESULTS: Mean follow-up for acute infection was 16.5 months (12.1 to 24.2) and 15.8 months (12 to 24.8) for chronic infections with unresectable components. Overall non-recurrence rates for acute infection was 92.3% (24/26) but only 44.4% (4/9) for chronic infections with unresectable components. The majority of patients remained on suppressive oral antibiotics. Musculoskeletal Infection Society (MSIS) host grade was a significant indicator of failure (p < 0.001). CONCLUSION: The addition of IO vancomycin at the time of DAIR was shown to be safe with improved results compared to current literature using standard DAIR without IO antibiotic administration. Use of this technique in chronic infections should be applied with caution. While these results are encouraging, this technique requires longer follow-up before widespread adoption. Cite this article: Bone Joint J 2021;103-B(6 Supple A):185-190.
引用
- Kildow BJ, Patel SP, Otero JE, et al. Results of debridement, antibiotics, and implant retention for periprosthetic knee joint infection supplemented with the use of intraosseous antibiotics. Bone Joint J. 2021. PMID: 34053280. doi:10.1302/0301-620X.103B6.BJJ-2020-2278.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。